Johnson & Johnson Family of Companies
1 Johnson & Johnson Plaza
New Brunswick
New Jersey
08933
United States
Tel: 732-524-0400
Fax: 732-524-3300
Website: http://www.jnj.com/
2402 articles with Johnson & Johnson Family of Companies
-
Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM.
-
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
-
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter 2021 Results
6/9/2021
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Wednesday, July 21st to review second-quarter results.
-
As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
A flurry of COVID-19 research news came out today. Here’s a look.
-
The biopharma industry strives to bring in more voices at the corporate level and clinical trials. But, there is still a long way to go, especially with companies helmed by minorities.
-
As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. FDA and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today.
-
Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.
-
Pfizer, Sagent Pharmaceuticals and Merck are preparing their antiviral pills against SARS-CoV-2 and are showing promise in new clinical trials.
-
Researchers at John Hopkins made their preliminary conclusions that the vaccines produced by Pfizer-BioNTech and Moderna did not cause the hearing loss.
-
Johnson & Johnson Medical Korea Ltd. & Johnson & Johnson Innovation LLC Announce Launch of Seoul Innovation QuickFire Challenge on Smart Surgery in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
5/20/2021
QuickFire Challenge calls on innovators to submit novel ideas with the potential to transform the surgical pathway for optimized care, cost savings, and improved patient outcomes.
-
The House Select Subcommittee on the Coronavirus Crisis questioned executives from Emergent BioSolutions as part of a congressional probe.
-
X-Vax Technology is preparing to submit an IND application to the U.S. FDA for its experimental vaccine against Herpes simplex virus 1 and 2 (HSV-1 and -2).
-
FDA says it is possible booster shots would be necessary for fully vaccinated individuals within a year even though vaccines are highly effective at COVID-19 prevention.
-
"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19
5/19/2021
Halberd Corporation was featured in a recent MarketWatch article, "New Approaches to Covid-19 Treatment Enter the Picture," along with six other notable biotechnology companies.
-
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
-
Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
5/13/2021
Up to 200,000 Johnson & Johnson Ebola vaccine regimens will be made available as part of a WHO early access clinical program now underway in Sierra Leone
-
There was a lot of news and research studies today related to the COVID-19 vaccines. Here’s a look.
-
Emergent company executives Fuad El-ibri and Robert Kramer will be testifying before a congressional probe after a botched batch of 15 million doses of J&J’s COVID-19 vaccine.